NewAmsterdam Pharma Co Stock (NASDAQ: NAMS)

Dernières nouvelles pour NewAmsterdam Pharma Co (NASDAQ:NAMS) Stock

NewAmsterdam Pharma

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

Mondelez International's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NYSE">MDLZ</a>) short percent of float has fallen 6.88% since its last report. The company recently reported that it has 20.35 million shares sold short, which is 1.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mondelez International Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751893232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mondelez International has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mondelez International's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mondelez International's peer group average for short interest as a percentage of float is 6.80%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

MDLZ

Peering Into Mondelez International's Recent Short Interest

BlackRock's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) short percent of float has risen 11.71% since its last report. The company recently reported that it has 1.89 million shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.56 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>BlackRock Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751893227_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for BlackRock has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing BlackRock's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, BlackRock's peer group average for short interest as a percentage of float is 3.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around BlackRock?

Mid-America Apartment's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) short percent of float has fallen 10.11% since its last report. The company recently reported that it has 4.24 million shares sold short, which is 4.98% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.96 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mid-America Apartment Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751893222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mid-America Apartment has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mid-America Apartment's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mid-America Apartment's peer group average for short interest as a percentage of float is 3.74%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

What's Driving the Market Sentiment Around Mid-America Apartment?

CYCCP

Trading Halt: Halt status updated at 9:00:00 AM ET: Quotation Resumption: News and Resumption Times

Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Gastrointestinal Cancers Congress (ESMO-GI) in Barcelona, Spain, along with regulatory updates from its July 1, 2025 End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA).
 FDA Meeting Outcomes
Official minutes from the July 1, 2025 End-of-Phase 2 (EoP2) meeting reflect a meaningful shift in FDA alignment since July 2024, establishing two new areas of agreement:
<ol>
<li>Contribution of components – FDA wrote that the current data "appears to support" balstilimab's contribution to the combination's clinical activity and therefore a registrational Phase 3 trial may proceed without a BOT monotherapy arm.</li>
<li>Phase 3 registrational trial –BATTMAN (CCTG CO.33): FDA and Agenus aligned on the core design of this global registration study for BOT/BAL. Agenus is incorporating the Agency's feedback and will initiate BATTMAN in Q4 2025.</li>
</ol>

News

AGEN

Agenus Confirms Agreement With FDA On Design Of Global BATTMAN Phase 3 Trial

Barclays analyst Alex Scott downgrades Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) from Overweight to Equal-Weight and lowers the price target from $280 to $274.

Downgrades

Price Target

Analyst Ratings

Barclays Downgrades Travelers Companies to Equal-Weight, Lowers Price Target to $274

Securities to be Purchased by Heights Capital Management, Inc.; Common Stock and Pre-Funded Warrants Sold at $55.49 per Share and Warrants at $99.88 Exercise Price
Investment Demonstrates IonQ's Unique Position in Commercial Quantum Computing and Networking
IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) ("IonQ" or the "Company"), a leading commercial quantum computing and networking company, today announced the pricing of a $1.0 billion equity offering consisting of 14,165,708 shares of IonQ's common stock, each at $55.49 per share, and pre-funded warrants to purchase 3,855,557 shares of IonQ's common stock, each at $55.49 per pre-funded warrant, each representing a premium of about 25% to IonQ's closing stock price on July 3, 2025, as well as seven-year warrants to purchase 36,042,530 additional shares of IonQ's common stock, for no additional consideration, at an exercise price of $99.88 per share. The securities offered will be purchased from the underwriter by Heights Capital Management, Inc. (the "investor").
Niccolo de Masi, President and CEO, of IonQ said, "IonQ is well-capitalized with a strong cash position and has been rapidly expanding our ecosystem as we execute against our global quantum computing and networking strategy. We believe this is the largest common-stock single-institutional investment in the history of the quantum industry. It is a tremendous validation of our technical momentum, recent acquisitions, IP, and talent density. With this transaction, IonQ will benefit from a balance sheet of approximately $1.68 billion of pro-forma cash as of March 31, 2025, underwriting our sustained growth and pioneering quantum commercialization worldwide."
J.P. Morgan acted as the sole underwriter in the transaction. Paul, Weiss, Rifkind, Wharton &amp; Garrison LLP served as legal counsel to IonQ. Simpson Thacher &amp; Bartlett LLP acted as legal counsel to J.P. Morgan. Skadden, Arps, Slate, Meagher &amp; Flom LLP acted as legal counsel to the investor.

Offerings

IONQ

IonQ Prices $1 Billion Equity Offering Of ~14.17M Shares And ~3.86M Pre-Funded Warrants At $55.49 Each; As Well As, ~36M 7-Year Warrants At $99.88 Exercise Price Purchased By Heights Capital Management

Agenus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) a leader in immuno-oncology innovation, today announced that its botensilimab and balstilimab (BOT/BAL) combination achieved a two-year survival rate of 42% along with a now more mature 21-month median overall survival (OS) in an expanded cohort of 123 patients with microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases (NLM). Agenus also confirmed that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of the global BATTMAN Phase 3 trial. The FDA waived the need for a BOT monotherapy arm, allowing for a simple two-arm study design. These new BOT/BAL data were reported at the 2025 ESMO Gastrointestinal Cancers Congress (ESMO-GI) in Barcelona, Spain, along with regulatory updates from its July 1, 2025 End-of-Phase 2 (EoP2) meeting with the U.S. Food and Drug Administration (FDA).

Agenus Says BOT/BAL Combination Achieves 2-Yr Survival Rate Of 42% Along With Now More Mature 21-Month Median OS In Expanded Cohort Of 123 Patients With MSS mCRC Without Active Liver Metastases

Barclays analyst Ramsey El-Assal initiates coverage on Chime Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHYM#NASDAQ">CHYM</a>) with a Overweight rating and announces Price Target of $40.

Initiation

CHYM

Barclays Initiates Coverage On Chime Financial with Overweight Rating, Announces Price Target of $40

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan raised Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) price target from $25 to $35. JP Morgan analyst Ekaterina Knyazkova upgraded the stock from Neutral to Overweight. Phibro Animal Health shares closed at $28.00 on Thursday. See how other analysts view this stock.</li>
<li>Jefferies cut the price target for ASGN Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASGN#NYSE">ASGN</a>) from $53 to $42. Jefferies analyst Surinder Thind downgraded the stock from Hold to Underperform. ASGN shares closed at $52.84 on Thursday. <a href="https://www.benzinga.com/quote/ASGN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Raymond James raised U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) price target from $51 to $57. Raymond James analyst Michael Rose upgraded the stock from Outperform to Strong Buy. U.S. Bancorp shares closed at $47.93 on Thursday. <a href="https://www.benzinga.com/quote/USB/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Constellation Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) from $194 to $205. Jefferies analyst Kaumil Gajrawala upgraded the stock from Hold to Buy. Constellation Brands shares closed at $172.32 on Thursday. <a href="https://www.benzinga.com/quote/STZ/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased the price target for MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) from $32 to $33. Jefferies analyst Laurence Alexander downgraded the stock from Buy to Hold. MP Materials shares closed at $31.84 on Thursday. <a href="https://www.benzinga.com/quote/MP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) price target from $4.9 to $7.2. Jefferies analyst Julien Dumoulin-Smith upgraded the stock from Hold to Buy. Shoals Technologies shares settled at $5.98 on Thursday. <a href="https://www.benzinga.com/quote/shls/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities cut Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) price target from $16.5 to $11.75. B of A Securities analyst Michael Jacks downgraded the stock from Buy to Neutral&nbsp;. Stellantis shares closed at $10.31 on Thursday. <a href="https://www.benzinga.com/quote/STLA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities increased Datadog, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DDOG#NASDAQ">DDOG</a>) price target from $150 to $175. B of A Securities analyst Koji Ikeda maintained a Buy rating. Datadog shares closed at $155.15 on Thursday.  <a href="https://www.benzinga.com/quote/DDOG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays cut the price target for Chubb Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from $321 to $298. Barclays analyst Alex Scott downgraded the stock from Overweight to Equal-Weight. Chubb shares settled at $283.80 on Thursday. <a href="https://www.benzinga.com/quote/CB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised XPO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NASDAQ">XPO</a>) price target from $139 to $150. B of A Securities analyst Ken Hoexter maintained a Buy rating. XPO shares closed at $132.13 on Thursday. <a href="https://www.benzinga.com/quote/XPO/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying USB stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/USB/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="602" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png" alt="" class="wp-image-974719" style="width:667px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-1024x602.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12-768x452.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07083842/image-1-12.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46243448/cramer-doesnt-recommend-titan-international-joby-aviation-soars-after-milestone-flight">Cramer Doesn&#8217;t Recommend Titan International, Joby Aviation Soars After Milestone Flight</a> </li>
</ul>
Photo via Shutterstock

Markets

ASGN

DDOG

DKNG

NVDA

PAHC

SHLS

STLA

U.S. Bancorp To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Monday

Inspira&#x2122; Technologies OXY B.H.N. Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IINN#NASDAQ">IINN</a>) ("Inspira," "Inspira Technologies," or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced that it is engaged in high-level talks with a government health authority, located outside of the United States, which are intended to advance the national integration of its FDA-cleared ART100 system as a foundational component of the national emergency infrastructure and to establish a global distribution framework.
The meeting, scheduled for July 8, 2025, is intended to define the key terms and roadmap for this strategic collaboration. These advanced discussions were initiated following a direct invitation from the government of the health authority, which is actively seeking to secure next-generation medical technologies and enhance national emergency readiness.
The government involved is recognized for its extensive commercial ties and diplomatic channels spanning the entire international community. Accordingly, the agenda will also feature the discussion relating to the establishment of a global distribution framework that leverages these unique capabilities with the aim to accelerate and increase the profitability of the $22.5 million purchase order received by Inspira, as announced on July 2, 2025.

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

Inspira Technologies In Talks With Government Health Authority To Advance National Integration Of FDA-Cleared ART100 System And To Establish Global Distribution Framework

LRHC

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">June 2025 Bitcoin Mining Updates (unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Key Metrics</td>
<td colspan="1" rowspan="1">Results (Rounded Numbers)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Bitcoins Mined During the Month</td>
<td colspan="1" rowspan="1">88 Bitcoins</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Bitcoins Owned by Canaan Inc. on Balance Sheet[1]</td>
<td colspan="1" rowspan="1">1,484 Bitcoins</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Deployed Hashrate (EH/s)</td>
<td colspan="1" rowspan="1">8.15 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Operating Hashrate (EH/s)</td>
<td colspan="1" rowspan="1">6.57 EH/s</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Average Revenue Split[2]</td>
<td colspan="1" rowspan="1">62.3&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Average All-in Power Cost During the Month[3]</td>
<td colspan="1" rowspan="1">US$0.045/kWh</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4" rowspan="1">June 2025 Bitcoin Mining Infrastructure Updates (unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">North America</td>
<td colspan="1" rowspan="1">Non-North America</td>
<td colspan="1" rowspan="1">Global</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Average Miner Efficiency</td>
<td colspan="1" rowspan="1">20.1 J/TH</td>
<td colspan="1" rowspan="1">29.7 J/TH</td>
<td colspan="1" rowspan="1">26.3 J/TH</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Month-End Installed Power Capacity</td>
<td colspan="1" rowspan="1">76.3 MW</td>
<td colspan="1" rowspan="1">139.6 MW</td>
<td colspan="1" rowspan="1">216.0 MW</td>
</tr>
</tbody>
</table>
</figure>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Canaan Provides June 2025 Bitcoin Production And Mining Operation Updates; 88 Bitcoins Mined During The Month

Evercore ISI Group analyst Steve Sakwa upgrades UDR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UDR#NYSE">UDR</a>) from In-Line to Outperform and raises the price target from $45 to $46.

Upgrades

Evercore ISI Group Upgrades UDR to Outperform, Raises Price Target to $46

Second Quarter Expectations and Revised Guidance
The Company expects net income in the range of $45 million to $55 million and adjusted EBITDA of approximately $135 million this quarter relative to its prior adjusted EBITDA guidance range of $120 million to $125 million. The Company has also increased its full year 2025 adjusted EBITDA guidance to a range of $530 million to $550 million from its original range of $520 million to $540 million.

Guidance

Element Solutions Raises Q2 Net Income Guidance To $45M-$55M And Adjusted EBITDA To ~$135M; Full-Year 2025 Adjusted EBITDA Forecast Increased From $520M-$540M To $530M-$550M

Barclays analyst Alex Scott initiates coverage on Ategrity Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIC#NYSE">ASIC</a>) with a Overweight rating and announces Price Target of $30.

ASIC

Barclays Initiates Coverage On Ategrity Specialty with Overweight Rating, Announces Price Target of $30

B of A Securities analyst Ken Hoexter maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $139 to $150.

B of A Securities Maintains Buy on XPO, Raises Price Target to $150

Barclays analyst Alex Scott downgrades Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) from Overweight to Equal-Weight and lowers the price target from $321 to $298.

Barclays Downgrades Chubb to Equal-Weight, Lowers Price Target to $298

WIIM

ALLT

Allot shares are trading higher after the company announced it secured a multi-million dollar deal to boost cybersecurity for a tier 1 EMEA telecom operator.

The United States is bracing for a potential acceleration in inflation, with a significant depreciation of the dollar now identified as a key contributing factor, according to a new analysis by Torsten Sløk, the chief economist at Apollo.
What Happened: As per Sløk&#8217;s <a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/">analysis</a>, a 10% depreciation in the U.S. dollar is projected to boost inflation by 0.3 percentage points.
This comes at a time when inflationary pressures are already building from multiple fronts, including ongoing tariffs, rising oil prices, and existing immigration restrictions.
Sløk emphasizes that &#8220;The bottom line is that we should see inflation move higher over the coming months; that is what the consensus expects, what the Fed expects, and what we expect.&#8221;
As the U.S. Dollar Index Spot has already declined by 10.29% on a year-to-date basis, a chart tracking the &#8220;Shock to Inflation, compared with consensus forecast&#8221; illustrates the projected impact.
A 10% depreciation occurring in the first half of a year (H1) shows a noticeable upward bump to inflation, as does a 10% depreciation in the second half (H2).
The chart also details the impact on U.S. CPI from both a 10% and a 20% depreciation in the dollar, relative to baseline forecasts, stretching from the first quarter of 2025 through the fourth quarter of 2027.
<figure class="wp-block-image size-large"><a href="https://www.apolloacademy.com/the-10-depreciation-in-the-dollar-will-boost-inflation-by-0-3-percentage-points/"><img loading="lazy" decoding="async" width="1024" height="563" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png" alt="" class="wp-image-974689" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-1024x563.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart-768x422.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07082234/Apollo-chart.png 1435w" sizes="(max-width: 1024px) 100vw, 1024px" /></a><figcaption class="wp-element-caption">Source: Apollo Academy</figcaption></figure>
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46269226/stocks-just-hit-rare-golden-cross-for-1st-time-since-2023-heres-what-it-means-for-investors">Stocks Just Hit Rare Golden Cross For 1st Time Since 2023 — Here&#8217;s What It Means For Investors</a>
Why It Matters: During a discussion with Blomberg Television, Sløk was asked about the business environment being stronger than consensus expectations in terms of hiring, without the inflationary impulse.
He said, &#8220;That brings us back to a discussion around what are the effects of the trade war? Are tariffs not going to have an impact? So far, it&#8217;s remarkable, where you have inflation still steady, and now the job growth still strong. So in that sense, there is literally very little sign of the trade war having a macroeconomic impact at this point.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Torsten Slok, chief economist at Apollo, reacts to the June US jobs report, which saw the unemployment rate move down to 4.1% with job growth that exceeded expectations for a fourth straight month <a href="https://t.co/ucnIBVQGMM">https://t.co/ucnIBVQGMM</a> <a href="https://t.co/VOhBqK7ZQY">pic.twitter.com/VOhBqK7ZQY</a>
&mdash; Bloomberg TV (@BloombergTV) <a href="https://twitter.com/BloombergTV/status/1940780912268001439?ref_src=twsrc%5Etfw">July 3, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The U.S. Dollar Index Spot was up 0.19% at the 97.3660 level during the publication of this article.
While, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Monday. The SPY was down 0.13% at $624.54, while the QQQ declined 0.25% to $554.81, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46271577/trumps-big-beautiful-bill-slashes-solar-incentives-cathie-woods-ark-says-nuclear-may-now-be-cheapest-option-oklo-smr-ltbr-and-other-stocks-in-focus">Trump&#8217;s Big Beautiful Bill Slashes Solar Incentives — Cathie Wood&#8217;s Ark Says Nuclear May Now Be Cheapest Option: OKLO, SMR, LTBR And Other Stocks In Focus </a></li>
</ul>
Image via Shutterstock

As US Dollar Sinks, Top Economist Warns 10% Slide Could Spark New Inflation Spike

Health Care

Press Releases

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Management

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Comments

NewAmsterdam Pharma Co

Actualités

Dernières nouvelles pour NewAmsterdam Pharma Co (NASDAQ:NAMS) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL